December 2, 2019 / 11:30 PM / 6 days ago

CORRECTED-Japan's Astellas Pharma to buy Audentes Therapeutics for $2.7 bln

(Corrects headline to say $2.7 billion, not $3 billion)

Dec 2 (Reuters) - Japan’s Astellas Pharma Inc said on Monday it had agreed to buy Audentes Therapeutics Inc for $2.7 billion in cash as it looks to bolster its position in the gene therapy market.

Astellas offer of $60 per share represents a 110% premium to Audentes closing price on Monday.

The deal is expected to close in the first quarter of 2020, the companies said in a statement. (Reporting by Dania Nadeem in Bengaluru; Editing by Anil D’Silva)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below